RepurpOS

Fibromyalgia

Disease intelligence for Fibromyalgia: 107 alterations and 462 ranked therapeutics from curated public databases.

US DALYs4.08MWHO GHE 2021 · all ages
Global DALYs45.69MWHO GHE 2021 · worldwide
US mortality12.5K deaths/yrWHO GHE 2021
Global mortality110.0K deaths/yrWHO GHE 2021 · worldwide
NIH funding$15MFY2025 · RCDC estimate
Funding levelSeverely Underfunded
Spontaneous remissionPartial spontaneous improvement in ~25-30% over 5 years; complete resolution without treatment rare; chronic…
Best-intervention remissionMultimodal approach (aerobic exercise + CBT + sleep optimisation): most effective combination — 50-60% significant…
Gap sizeLarge — pharmacotherapy is modestly effective; exercise is the most effective single intervention but chronically…
Primary barrierframing/practice
Full remission profile →

Disease overview

Alterations
107
Molecular (A)
100
Clinical (B–E)
7
Direct drugs
103
Via biomarker
360
Natural agents
0
Natural products
60
Merged ranked
462
With trial/literature evidence
25

Sources: Open Targets, HPO, ClinicalTrials.gov, DGIdb, ChEMBL, PubMed Literature, Seeds, GreenMedInfo · Pipeline phase 7 · Updated 2026-07-06

Remission & chronicity

Spontaneous remission
Partial spontaneous improvement in ~25-30% over 5 years; complete resolution without treatment rare; chronic fluctuating course in majority; central sensitisation often persists
Best-intervention remission
Multimodal approach (aerobic exercise + CBT + sleep optimisation): most effective combination — 50-60% significant improvement; duloxetine: 50% pain response in 43% vs 29% placebo; milnacipran: similar; pregabalin: 50% pain response 38-50%; low-dose naltrexone (LDN): 30% improvement in open-label studies
Drug-free remission
Relapse after remission
Chronicity
Gap size
Large — pharmacotherapy is modestly effective; exercise is the most effective single intervention but chronically underused as 'too painful'; disease is often dismissed
Primary barrier
framing/practice
Barrier detail: Fibromyalgia was dismissed as non-organic by mainstream medicine for decades; this has resulted in: delayed diagnosis (mean 5 years), inappropriate investigations, ineffective treatments (opioids in particular), and under-referral to physiotherapy and psychological therapies; the 2010 ACR criteria removed tender point requirement and improved diagnosis

Last SoC change: 2021 — 2021 update to EULAR fibromyalgia recommendations; milnacipran/duloxetine/pregabalin approvals 2007-2008; these remain the only FDA-approved drugs for fibromyalgia; tricyclics (amitriptyline) off-label since 1980s

Remission data layers: disease_db_100 · source-locked manual data · confidence: high

Identifiers: MONDO: MONDO:0005546

Alterations

Showing 80 of 107 · Types A (molecular) through E (functional)

NameTypeSubtypeDirection FrequencyEvidenceSourcesLinks
ACHE
acetylcholinesterase (Yt blood group)
Molecular Gene Emerging Open Targets
ADRA1A
adrenoceptor alpha 1A
Molecular Gene Emerging Open Targets
ADRA2A
adrenoceptor alpha 2A
Molecular Gene Emerging Open Targets
ADRA2B
adrenoceptor alpha 2B
Molecular Gene Emerging Open Targets
ADRA2C
adrenoceptor alpha 2C
Molecular Gene Emerging Open Targets
ADRB1
adrenoceptor beta 1
Molecular Gene Emerging Open Targets
ADRB2
adrenoceptor beta 2
Molecular Gene Emerging Open Targets
ADRB3
adrenoceptor beta 3
Molecular Gene Emerging Open Targets
Beck Depression Inventory Scales & PROs Clinical scale Emerging ClinicalTrials.gov
Body Image Perception Lab / Clinical Lab value Emerging ClinicalTrials.gov
CACNA1A
calcium voltage-gated channel subunit alpha1 A
Molecular Gene Emerging Open Targets
CACNA1B
calcium voltage-gated channel subunit alpha1 B
Molecular Gene Emerging Open Targets
CACNA1C
calcium voltage-gated channel subunit alpha1 C
Molecular Gene Emerging Open Targets
CACNA1D
calcium voltage-gated channel subunit alpha1 D
Molecular Gene Emerging Open Targets
CACNA1E
calcium voltage-gated channel subunit alpha1 E
Molecular Gene Emerging Open Targets
CACNA1F
calcium voltage-gated channel subunit alpha1 F
Molecular Gene Emerging Open Targets
CACNA1G
calcium voltage-gated channel subunit alpha1 G
Molecular Gene Emerging Open Targets
CACNA1H
calcium voltage-gated channel subunit alpha1 H
Molecular Gene Emerging Open Targets
CACNA1I
calcium voltage-gated channel subunit alpha1 I
Molecular Gene Emerging Open Targets
CACNA1S
calcium voltage-gated channel subunit alpha1 S
Molecular Gene Emerging Open Targets
CACNA2D1
calcium voltage-gated channel auxiliary subunit alpha2delta 1
Molecular Gene Emerging Open Targets
CACNA2D2
calcium voltage-gated channel auxiliary subunit alpha2delta 2
Molecular Gene Emerging Open Targets
CACNA2D3
calcium voltage-gated channel auxiliary subunit alpha2delta 3
Molecular Gene Emerging Open Targets
CACNA2D4
calcium voltage-gated channel auxiliary subunit alpha2delta 4
Molecular Gene Emerging Open Targets
CACNB1
calcium voltage-gated channel auxiliary subunit beta 1
Molecular Gene Emerging Open Targets
CACNB2
calcium voltage-gated channel auxiliary subunit beta 2
Molecular Gene Emerging Open Targets
CACNB3
calcium voltage-gated channel auxiliary subunit beta 3
Molecular Gene Emerging Open Targets
CACNB4
calcium voltage-gated channel auxiliary subunit beta 4
Molecular Gene Emerging Open Targets
CACNG1
calcium voltage-gated channel auxiliary subunit gamma 1
Molecular Gene Emerging Open Targets
CACNG2
calcium voltage-gated channel auxiliary subunit gamma 2
Molecular Gene Emerging Open Targets
CACNG3
calcium voltage-gated channel auxiliary subunit gamma 3
Molecular Gene Emerging Open Targets
CACNG4
calcium voltage-gated channel auxiliary subunit gamma 4
Molecular Gene Emerging Open Targets
CACNG5
calcium voltage-gated channel auxiliary subunit gamma 5
Molecular Gene Emerging Open Targets
CACNG6
calcium voltage-gated channel auxiliary subunit gamma 6
Molecular Gene Emerging Open Targets
CACNG7
calcium voltage-gated channel auxiliary subunit gamma 7
Molecular Gene Emerging Open Targets
CACNG8
calcium voltage-gated channel auxiliary subunit gamma 8
Molecular Gene Emerging Open Targets
CALCRL
calcitonin receptor like receptor
Molecular Gene Emerging Open Targets
CD274
CD274 molecule
Molecular Gene Emerging Open Targets
CNR1
cannabinoid receptor 1
Molecular Gene Emerging Open Targets
COXFA4L2
cytochrome c oxidase hypoxia associated subunit FA4L2
Molecular Gene Emerging Open Targets
DRD2
dopamine receptor D2
Molecular Gene Emerging Open Targets
DRD3
dopamine receptor D3
Molecular Gene Emerging Open Targets
DRD4
dopamine receptor D4
Molecular Gene Emerging Open Targets
Fibromyalgia Impact Questionnaire (FIQ) Scales & PROs Clinical scale Emerging ClinicalTrials.gov
GABBR1
gamma-aminobutyric acid type B receptor subunit 1
Molecular Gene Emerging Open Targets
GABBR2
gamma-aminobutyric acid type B receptor subunit 2
Molecular Gene Emerging Open Targets
GABRA1
gamma-aminobutyric acid type A receptor subunit alpha1
Molecular Gene Emerging Open Targets
GHR
growth hormone receptor
Molecular Gene Emerging Open Targets
GHSR
growth hormone secretagogue receptor
Molecular Gene Emerging Open Targets
GRIN1
glutamate ionotropic receptor NMDA type subunit 1
Molecular Gene Emerging Open Targets
GRIN2A
glutamate ionotropic receptor NMDA type subunit 2A
Molecular Gene Emerging Open Targets
GRIN2B
glutamate ionotropic receptor NMDA type subunit 2B
Molecular Gene Emerging Open Targets
GRIN2C
glutamate ionotropic receptor NMDA type subunit 2C
Molecular Gene Emerging Open Targets
GRIN2D
glutamate ionotropic receptor NMDA type subunit 2D
Molecular Gene Emerging Open Targets
GRIN3A
glutamate ionotropic receptor NMDA type subunit 3A
Molecular Gene Emerging Open Targets
GRIN3B
glutamate ionotropic receptor NMDA type subunit 3B
Molecular Gene Emerging Open Targets
HRH1
histamine receptor H1
Molecular Gene Emerging Open Targets
HTR2A
5-hydroxytryptamine receptor 2A
Molecular Gene Emerging Open Targets
HTR2C
5-hydroxytryptamine receptor 2C
Molecular Gene Emerging Open Targets
HTR3A
5-hydroxytryptamine receptor 3A
Molecular Gene Emerging Open Targets
HTR3B
5-hydroxytryptamine receptor 3B
Molecular Gene Emerging Open Targets
HTR3C
5-hydroxytryptamine receptor 3C
Molecular Gene Emerging Open Targets
HTR3D
5-hydroxytryptamine receptor 3D
Molecular Gene Emerging Open Targets
HTR3E
5-hydroxytryptamine receptor 3E
Molecular Gene Emerging Open Targets
IFNAR1
interferon alpha and beta receptor subunit 1
Molecular Gene Emerging Open Targets
IFNAR2
interferon alpha and beta receptor subunit 2
Molecular Gene Emerging Open Targets
LEP
leptin
Molecular Gene Emerging Open Targets
MMP3
matrix metallopeptidase 3
Molecular Gene Emerging Open Targets
MT-ND6
mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6
Molecular Gene Emerging Open Targets
MTNR1A
melatonin receptor 1A
Molecular Gene Emerging Open Targets
MTNR1B
melatonin receptor 1B
Molecular Gene Emerging Open Targets
NDUFA1
NADH:ubiquinone oxidoreductase subunit A1
Molecular Gene Emerging Open Targets
NDUFA11
NADH:ubiquinone oxidoreductase subunit A11
Molecular Gene Emerging Open Targets
NDUFA3
NADH:ubiquinone oxidoreductase subunit A3
Molecular Gene Emerging Open Targets
NDUFAB1
NADH:ubiquinone oxidoreductase subunit AB1
Molecular Gene Emerging Open Targets
NDUFAF4
NADH:ubiquinone oxidoreductase complex assembly factor 4
Molecular Gene Emerging Open Targets
NDUFB1
NADH:ubiquinone oxidoreductase subunit B1
Molecular Gene Emerging Open Targets
NDUFB2
NADH:ubiquinone oxidoreductase subunit B2
Molecular Gene Emerging Open Targets
NDUFB3
NADH:ubiquinone oxidoreductase subunit B3
Molecular Gene Emerging Open Targets
NDUFB7
NADH:ubiquinone oxidoreductase subunit B7
Molecular Gene Emerging Open Targets

Therapeutics

Direct disease associations, biomarker-linked drugs, OSMF narrative-review natural agents, merged ranking, and clinical trial / literature evidence (top agents)

DrugTypePhaseEvidence ScoreTrials & literatureSourcesLinks
IMIPRAMINE Small molecule Approved Strong 100
1 trials 1 Meta-analysis
View evidence

Registry trials

  • NCT04832100 — Bio-significance of LPC16:0 in Fibromyalgia (RECRUITING)

Published literature

Open Targets, ChEMBL
ACEBUTOLOL Repurposing Small molecule Approved Strong 95 DGIdb
ACEBUTOLOL HYDROCHLORIDE Repurposing Small molecule Approved Strong 95 DGIdb
ACETAZOLAMIDE Repurposing Small molecule Approved Strong 95 ChEMBL
ALBUTEROL SULFATE Repurposing Small molecule Approved Strong 95 DGIdb
ALFUZOSIN Repurposing Small molecule Approved Strong 95 DGIdb
ALFUZOSIN HYDROCHLORIDE Repurposing Small molecule Approved Strong 95 DGIdb
AMBENONIUM Repurposing Small molecule Approved Strong 95 DGIdb
AMBENONIUM CHLORIDE Repurposing Small molecule Approved Strong 95 DGIdb
AMIODARONE HYDROCHLORIDE Repurposing Small molecule Approved Strong 95 DGIdb
AMITRIPTYLINE HYDROCHLORIDE Repurposing Small molecule Approved Strong 95 DGIdb
AMLODIPINE BENZOATE Repurposing Small molecule Approved Strong 95 DGIdb
AMLODIPINE BESYLATE Repurposing Small molecule Approved Strong 95 DGIdb
AMLODIPINE BESYLATE Repurposing Small molecule Approved Strong 95 DGIdb
AMLODIPINE MALEATE Repurposing Small molecule Approved Strong 95 DGIdb
AMPHETAMINE Repurposing Small molecule Approved Strong 95 ChEMBL
APIGENIN Repurposing Small molecule Approved Strong 95 DGIdb
APOMORPHINE Repurposing Small molecule Approved Strong 95 DGIdb
APRACLONIDINE Repurposing Small molecule Approved Strong 95 DGIdb
APRACLONIDINE HYDROCHLORIDE Repurposing Small molecule Approved Strong 95 DGIdb
ARBUTAMINE Repurposing Small molecule Approved Strong 95 DGIdb
ARFORMOTEROL Repurposing Small molecule Approved Strong 95 DGIdb
ARFORMOTEROL TARTRATE Repurposing Small molecule Approved Strong 95 DGIdb
ASENAPINE Repurposing Small molecule Approved Strong 95 DGIdb
ATENOLOL Repurposing Small molecule Approved Strong 95 DGIdb
ATIPAMEZOLE Repurposing Small molecule Approved Strong 95 DGIdb
ATROPINE Repurposing Small molecule Approved Strong 95 DGIdb
BENZGALANTAMINE GLUCONATE Repurposing Small molecule Approved Strong 95 DGIdb
BENZPHETAMINE Repurposing Small molecule Approved Strong 95 DGIdb
BEPRIDIL Repurposing Small molecule Approved Strong 95 DGIdb
BEPRIDIL HYDROCHLORIDE Repurposing Small molecule Approved Strong 95 DGIdb
BETAMETHASONE Repurposing Small molecule Approved Strong 95 DGIdb
BETAXOLOL Repurposing Small molecule Approved Strong 95 DGIdb
BETAXOLOL HYDROCHLORIDE Repurposing Small molecule Approved Strong 95 DGIdb
BETHANIDINE Repurposing Small molecule Approved Strong 95 DGIdb
BICALUTAMIDE Repurposing Small molecule Approved Strong 95 ChEMBL
BISOPROLOL Repurposing Small molecule Approved Strong 95 DGIdb
BISOPROLOL FUMARATE Repurposing Small molecule Approved Strong 95 DGIdb
BITOLTEROL MESYLATE Repurposing Small molecule Approved Strong 95 DGIdb
BRETYLIUM Repurposing Small molecule Approved Strong 95 DGIdb
BRIMONIDINE Repurposing Small molecule Approved Strong 95 DGIdb
BRIMONIDINE TARTRATE Repurposing Small molecule Approved Strong 95 DGIdb
BROMOCRIPTINE Repurposing Small molecule Approved Strong 95 DGIdb
CABERGOLINE Repurposing Small molecule Approved Strong 95 DGIdb
CARBACHOL Repurposing Small molecule Approved Strong 95 ChEMBL
CARTEOLOL Repurposing Small molecule Approved Strong 95 DGIdb
CARTEOLOL HYDROCHLORIDE Repurposing Small molecule Approved Strong 95
No indexed hits
View evidence
DGIdb
CARVEDILOL Repurposing Small molecule Approved Strong 95
No indexed hits
View evidence
DGIdb
CARVEDILOL PHOSPHATE Repurposing Small molecule Approved Strong 95
No indexed hits
View evidence
DGIdb
CELECOXIB Repurposing Small molecule Approved Strong 95 DGIdb
DrugTypePhaseEvidence ScoreTrials & literatureSourcesLinks
AMITRIPTYLINE Small molecule Phase III Moderate 80 Open Targets
CANNABIDIOL Small molecule Phase III Moderate 80 Open Targets
CYCLOBENZAPRINE Small molecule Phase III Moderate 80 Open Targets
CYCLOBENZAPRINE HYDROCHLORIDE Small molecule Phase III Moderate 80 Open Targets
DOLASETRON Small molecule Phase III Moderate 80 Open Targets
DULOXETINE Small molecule Phase III Moderate 80 Open Targets
ERENUMAB Biologic Phase III Moderate 80 Open Targets
ESREBOXETINE Small molecule Phase III Moderate 80 Open Targets
FERRIC CARBOXYMALTOSE Small molecule Phase III Moderate 80 Open Targets
FERRIC OXYHYDROXIDE Small molecule Phase III Moderate 80 Open Targets
FERROUS SULFATE Small molecule Phase III Moderate 80 Open Targets
GABAPENTIN Small molecule Phase III Moderate 80 Open Targets
IRON ISOMALTOSIDE 1000 Small molecule Phase III Moderate 80 Open Targets
KETOTIFEN Small molecule Phase III Moderate 80 Open Targets
LIDOCAINE Small molecule Phase III Moderate 80 Open Targets
MEMANTINE Small molecule Phase III Moderate 80 Open Targets
MILNACIPRAN Small molecule Phase III Moderate 80 Open Targets
MIROGABALIN Small molecule Phase III Moderate 80 Open Targets
REBOXETINE Small molecule Phase III Moderate 80 Open Targets
SODIUM OXYBATE Small molecule Phase III Moderate 80 Open Targets
SOMATROPIN Biologic Phase III Moderate 80 Open Targets
TRAMADOL Small molecule Phase III Moderate 80 Open Targets
AMPRELOXETINE Small molecule Phase II Emerging 60 Open Targets
BCG VACCINE Small molecule Phase II Emerging 60 Open Targets
CARBIDOPA Small molecule Phase II Emerging 60 Open Targets
CYCLOSERINE Small molecule Phase II Emerging 60 Open Targets
DESVENLAFAXINE Small molecule Phase II Emerging 60 Open Targets
DESVENLAFAXINE SUCCINATE Small molecule Phase II Emerging 60 Open Targets
DEXAMETHASONE Small molecule Phase II Emerging 60 Open Targets
DEXTROMETHORPHAN Small molecule Phase II Emerging 60 Open Targets
DRONABINOL Small molecule Phase II Emerging 60 Open Targets
DROXIDOPA Small molecule Phase II Emerging 60 Open Targets
ESCITALOPRAM Small molecule Phase II Emerging 60 Open Targets
ESLICARBAZEPINE ACETATE Small molecule Phase II Emerging 60 Open Targets
FAMCICLOVIR Small molecule Phase II Emerging 60 Open Targets
FAXELADOL Small molecule Phase II Emerging 60 Open Targets
FLUPIRTINE Small molecule Phase II Emerging 60 Open Targets
FREMANEZUMAB Biologic Phase II Emerging 60 Open Targets
IBUTAMOREN MESYLATE Small molecule Phase II Emerging 60 Open Targets
IMIPRAMINE Small molecule Phase II Emerging 60
1 trials 1 Meta-analysis
View evidence

Registry trials

  • NCT04832100 — Bio-significance of LPC16:0 in Fibromyalgia (RECRUITING)

Published literature

Open Targets
DrugTypePhaseEvidence ScoreSourcesLinks
ACEBUTOLOL Repurposing via ADRA2C Small molecule Approved Strong 95 DGIdb
ACEBUTOLOL HYDROCHLORIDE Repurposing via ADRB1 Small molecule Approved Strong 95 DGIdb
ACETAZOLAMIDE Repurposing via ACHE Small molecule Approved Strong 95 ChEMBL
ALBUTEROL SULFATE Repurposing via ADRB2 Small molecule Approved Strong 95 DGIdb
ALFUZOSIN Repurposing via ADRA1A Small molecule Approved Strong 95 DGIdb
ALFUZOSIN HYDROCHLORIDE Repurposing via ADRA1A Small molecule Approved Strong 95 DGIdb
AMBENONIUM Repurposing via ACHE Small molecule Approved Strong 95 DGIdb
AMBENONIUM CHLORIDE Repurposing via ACHE Small molecule Approved Strong 95 DGIdb
AMIODARONE HYDROCHLORIDE Repurposing via ADRA1A Small molecule Approved Strong 95 DGIdb
AMITRIPTYLINE HYDROCHLORIDE Repurposing via ADRA1A Small molecule Approved Strong 95 DGIdb
AMLODIPINE BENZOATE Repurposing via CACNA1F Small molecule Approved Strong 95 DGIdb
AMLODIPINE BESYLATE Repurposing via CACNA1F Small molecule Approved Strong 95 DGIdb
AMLODIPINE BESYLATE Repurposing via CACNA1C Small molecule Approved Strong 95 DGIdb
AMLODIPINE MALEATE Repurposing via CACNA1F Small molecule Approved Strong 95 DGIdb
AMPHETAMINE Repurposing via ACHE Small molecule Approved Strong 95 ChEMBL
APIGENIN Repurposing via ACHE Small molecule Approved Strong 95 DGIdb
APOMORPHINE Repurposing via ADRA2C Small molecule Approved Strong 95 DGIdb
APRACLONIDINE Repurposing via ADRA2C Small molecule Approved Strong 95 DGIdb
APRACLONIDINE HYDROCHLORIDE Repurposing via ADRA2C Small molecule Approved Strong 95 DGIdb
ARBUTAMINE Repurposing via ADRB1 Small molecule Approved Strong 95 DGIdb
ARFORMOTEROL Repurposing via ADRB2 Small molecule Approved Strong 95 DGIdb
ARFORMOTEROL TARTRATE Repurposing via ADRB2 Small molecule Approved Strong 95 DGIdb
ASENAPINE Repurposing via ADRA2C Small molecule Approved Strong 95 DGIdb
ATENOLOL Repurposing via ADRA2C Small molecule Approved Strong 95 DGIdb
ATIPAMEZOLE Repurposing via ADRA2C Small molecule Approved Strong 95 DGIdb
ATROPINE Repurposing via ADRA2A Small molecule Approved Strong 95 DGIdb
BENZGALANTAMINE GLUCONATE Repurposing via ACHE Small molecule Approved Strong 95 DGIdb
BENZPHETAMINE Repurposing via ADRA1A Small molecule Approved Strong 95 DGIdb
BEPRIDIL Repurposing via CACNA1A Small molecule Approved Strong 95 DGIdb
BEPRIDIL HYDROCHLORIDE Repurposing via CACNA1G Small molecule Approved Strong 95 DGIdb
BETAMETHASONE Repurposing via ACHE Small molecule Approved Strong 95 DGIdb
BETAXOLOL Repurposing via ADRA2C Small molecule Approved Strong 95 DGIdb
BETAXOLOL HYDROCHLORIDE Repurposing via ADRB1 Small molecule Approved Strong 95 DGIdb
BETHANIDINE Repurposing via ADRA2C Small molecule Approved Strong 95 DGIdb
BICALUTAMIDE Repurposing via ACHE Small molecule Approved Strong 95 ChEMBL
BISOPROLOL Repurposing via ADRA2C Small molecule Approved Strong 95 DGIdb
BISOPROLOL FUMARATE Repurposing via ADRB1 Small molecule Approved Strong 95 DGIdb
BITOLTEROL MESYLATE Repurposing via ADRB2 Small molecule Approved Strong 95 DGIdb
BRETYLIUM Repurposing via ADRB1 Small molecule Approved Strong 95 DGIdb
BRIMONIDINE Repurposing via ADRA2C Small molecule Approved Strong 95 DGIdb

Natural Products

60 natural products with the same evidence schema as repurposed drugs — registry trials, PubMed literature, and reference links (pipeline-ranked)

Reference lookups: GreenMedInfo · Examine.com

DrugTypePhaseEvidence ScoreTrials & literatureSourcesLinks
Magnesium Natural product Nutraceutical Phase II Moderate 20
8 trials 2 Cochrane 6 RCT
View evidence

Registry trials

  • NCT06595017 — Lidocaine Versus Magnesium Sulphate in Management of Myofascial Pain Dysfunction Syndrome (NOT_YET_RECRUITING) PHASE2
  • NCT07390851 — Magnesium Sulfate as an Adjuvant to Lidocaine in MPDS Trigger Point Injections Assessed by VAS and sEMG. (RECRUITING) NA
  • NCT07519824 — The Role of Bioelements in Fibromyalgia: Disease Activity or Depression-Anxiety? (COMPLETED)
  • NCT05389761 — Fibromyalgia Treatment With Enzyme DAO (COMPLETED) NA
  • NCT04158388 — Effects of Nutritional Strategies or Manual Therapies in Women With Fibromyalgia (COMPLETED) NA
  • NCT01460680 — Membrane Polyunsaturated Fatty Acid Content in Fibromyalgia and Systemic Lupus Erythematosus (SLE) (UNKNOWN)
  • NCT06975813 — Magnesium Sulfate and Trigger Points (NOT_YET_RECRUITING) PHASE2
  • NCT03887000 — Magnesium, Stress and Fibromyalgia (COMPLETED) NA

Published literature

Examine.com, GreenMedInfo
Vitamin D3 Natural product Nutraceutical Approved Moderate 20
8 trials
View evidence

Registry trials

  • NCT04301609 — Clinical Trial to Assess the Improvement of Fatigue, Sleep Problems, Anxiety / Depression, Neurovegetatives Alterations and Quality of Life After the Administration of ImmunoVita® in Chronic Fatigue Syndrome Patients (COMPLETED) NA
  • NCT07013305 — Pre- and Post-Treatment Investigation of B12 and Folic Acid (Folate) Levels in Patients Receiving Antiepileptic (Anticonvulsant) Treatment for Fibromyalgia: Retrospective Study (COMPLETED)
  • NCT03369379 — Valuation of Efficacy and Safety of Vitamin D3 Use in 80 Women Diagnosed With Fibromyalgia. Using FIQ Score and VAS. (COMPLETED) PHASE4
  • NCT07649824 — Isokinetic Muscle Strength, Torque, Ultrasonographic Muscle Thickness in Fibromyalgia Syndrome: A Case-Control Study (COMPLETED)
  • NCT04845737 — Electrophysiological Findings in Fibromyalgia Patients (COMPLETED) NA
  • NCT06111573 — Comparative Evaluation of the Effectiveness of Diclofenac Sodium Versus Vitamin D on Myofascial Pain (COMPLETED) PHASE4
  • NCT06969716 — Frequency of Fibromyalgia Syndrome in Elderly Patients Aged 80 and Above and Its Relationship With Geriatric Parameters (COMPLETED)
  • NCT04892602 — Fibromyalgia in Rheumatiod and Psoriatic Patients (COMPLETED)

Examine.com, GreenMedInfo
Vitamin D3 Natural product Nutraceutical Approved Emerging 19
8 trials
View evidence

Registry trials

  • NCT04301609 — Clinical Trial to Assess the Improvement of Fatigue, Sleep Problems, Anxiety / Depression, Neurovegetatives Alterations and Quality of Life After the Administration of ImmunoVita® in Chronic Fatigue Syndrome Patients (COMPLETED) NA
  • NCT07013305 — Pre- and Post-Treatment Investigation of B12 and Folic Acid (Folate) Levels in Patients Receiving Antiepileptic (Anticonvulsant) Treatment for Fibromyalgia: Retrospective Study (COMPLETED)
  • NCT03369379 — Valuation of Efficacy and Safety of Vitamin D3 Use in 80 Women Diagnosed With Fibromyalgia. Using FIQ Score and VAS. (COMPLETED) PHASE4
  • NCT07649824 — Isokinetic Muscle Strength, Torque, Ultrasonographic Muscle Thickness in Fibromyalgia Syndrome: A Case-Control Study (COMPLETED)
  • NCT04845737 — Electrophysiological Findings in Fibromyalgia Patients (COMPLETED) NA
  • NCT06111573 — Comparative Evaluation of the Effectiveness of Diclofenac Sodium Versus Vitamin D on Myofascial Pain (COMPLETED) PHASE4
  • NCT06969716 — Frequency of Fibromyalgia Syndrome in Elderly Patients Aged 80 and Above and Its Relationship With Geriatric Parameters (COMPLETED)
  • NCT04892602 — Fibromyalgia in Rheumatiod and Psoriatic Patients (COMPLETED)

Examine.com
Magnesium Natural product Nutraceutical Phase II Emerging 19
8 trials 2 Cochrane 6 RCT
View evidence

Registry trials

  • NCT06595017 — Lidocaine Versus Magnesium Sulphate in Management of Myofascial Pain Dysfunction Syndrome (NOT_YET_RECRUITING) PHASE2
  • NCT07390851 — Magnesium Sulfate as an Adjuvant to Lidocaine in MPDS Trigger Point Injections Assessed by VAS and sEMG. (RECRUITING) NA
  • NCT07519824 — The Role of Bioelements in Fibromyalgia: Disease Activity or Depression-Anxiety? (COMPLETED)
  • NCT05389761 — Fibromyalgia Treatment With Enzyme DAO (COMPLETED) NA
  • NCT04158388 — Effects of Nutritional Strategies or Manual Therapies in Women With Fibromyalgia (COMPLETED) NA
  • NCT01460680 — Membrane Polyunsaturated Fatty Acid Content in Fibromyalgia and Systemic Lupus Erythematosus (SLE) (UNKNOWN)
  • NCT06975813 — Magnesium Sulfate and Trigger Points (NOT_YET_RECRUITING) PHASE2
  • NCT03887000 — Magnesium, Stress and Fibromyalgia (COMPLETED) NA

Published literature

Examine.com
Chlorella Natural product Nutraceutical Preclinical Moderate 17
No indexed hits
View evidence
Examine.com
Coenzyme Q10 Natural product Nutraceutical Preclinical Moderate 17 Examine.com, GreenMedInfo
L-Carnitine Natural product Amino acid Preclinical Moderate 17
1 Cochrane 3 Trial pubs
View evidence
Examine.com, GreenMedInfo
Saffron Natural product Botanical Preclinical Moderate 17
1 Cochrane
View evidence
Examine.com, GreenMedInfo
Creatine Natural product Amino acid Preclinical Moderate 17
2 trials 6 Trial pubs
View evidence

Registry trials

  • NCT06675708 — Effectiveness of Creatine on Pain, Fatigue, and Muscle Architectural Variables in Patients Witg Fibromyalgia. (ENROLLING_BY_INVITATION) NA
  • NCT00749983 — Effects of Creatine Supplementation in Women With Knee Osteoarthritis and Fibromyalgia (COMPLETED) NA

Published literature

Examine.com
Iron Natural product Nutraceutical Approved Moderate 17
6 trials 1 RCT
View evidence

Registry trials

  • NCT01820052 — A Randomized Trial of Oral Iron Therapy in Fibromyalgia (COMPLETED) PHASE3
  • NCT07519824 — The Role of Bioelements in Fibromyalgia: Disease Activity or Depression-Anxiety? (COMPLETED)
  • NCT05067998 — The Benefits of Natural Medicine, Vitamin IV Therapy and Supplements: Maintaining Good Health Through Nature (RECRUITING)
  • NCT06665516 — Frequency and Impact of Iron Deficiency in Pain Clinic Patients (COMPLETED)
  • NCT02409459 — Blinded Randomized Placebo-Controlled Study Efficacy and Safety of Injectafer in ID Patients With Fibromyalgia (COMPLETED) PHASE2
  • NCT00673608 — Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload (COMPLETED) PHASE4

Published literature

Examine.com
Iron Natural product Nutraceutical Approved Emerging 16
6 trials 1 RCT
View evidence

Registry trials

  • NCT01820052 — A Randomized Trial of Oral Iron Therapy in Fibromyalgia (COMPLETED) PHASE3
  • NCT07519824 — The Role of Bioelements in Fibromyalgia: Disease Activity or Depression-Anxiety? (COMPLETED)
  • NCT05067998 — The Benefits of Natural Medicine, Vitamin IV Therapy and Supplements: Maintaining Good Health Through Nature (RECRUITING)
  • NCT06665516 — Frequency and Impact of Iron Deficiency in Pain Clinic Patients (COMPLETED)
  • NCT02409459 — Blinded Randomized Placebo-Controlled Study Efficacy and Safety of Injectafer in ID Patients With Fibromyalgia (COMPLETED) PHASE2
  • NCT00673608 — Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload (COMPLETED) PHASE4

Published literature

Examine.com
Creatine Natural product Amino acid Phase I Emerging 13
2 trials 6 Trial pubs
View evidence

Registry trials

  • NCT06675708 — Effectiveness of Creatine on Pain, Fatigue, and Muscle Architectural Variables in Patients Witg Fibromyalgia. (ENROLLING_BY_INVITATION) NA
  • NCT00749983 — Effects of Creatine Supplementation in Women With Knee Osteoarthritis and Fibromyalgia (COMPLETED) NA

Published literature

Examine.com
S-Adenosylmethionine Natural product Nutraceutical Phase II Moderate 13
1 trials 1 RCT
View evidence

Registry trials

  • NCT00528710 — Efficacy of S-Adenosylmethionine in Fibromyalgia (COMPLETED) PHASE2

Published literature

Examine.com
Coenzyme Q10 Natural product Nutraceutical Phase I Emerging 10 Examine.com
Calcium Natural product Nutraceutical Preclinical Emerging 10
1 trials 1 Meta-analysis 2 RCT
View evidence

Registry trials

  • NCT05067998 — The Benefits of Natural Medicine, Vitamin IV Therapy and Supplements: Maintaining Good Health Through Nature (RECRUITING)

Published literature

GreenMedInfo
Vitamin B12 Natural product Nutraceutical Phase II Emerging 10
4 trials
View evidence

Registry trials

  • NCT07013305 — Pre- and Post-Treatment Investigation of B12 and Folic Acid (Folate) Levels in Patients Receiving Antiepileptic (Anticonvulsant) Treatment for Fibromyalgia: Retrospective Study (COMPLETED)
  • NCT05067998 — The Benefits of Natural Medicine, Vitamin IV Therapy and Supplements: Maintaining Good Health Through Nature (RECRUITING)
  • NCT06804460 — Effect of a Vegan Mediterranean Diet on Cardiometabolic Biomarkers, Functional Capacity, and Quality of Life in Patients with Fibromyalgia (NOT_YET_RECRUITING) PHASE1
  • NCT05008042 — Evaluation of the Efficiacy of Mecobalamine in the Treatment of Long-term Pain in Women Diagnosed With Fibromyalgia (COMPLETED) PHASE1, PHASE2

Published literature

GreenMedInfo
Vitamin C Natural product Nutraceutical Preclinical Emerging 10
1 trials 1 RCT
View evidence

Registry trials

  • NCT05067998 — The Benefits of Natural Medicine, Vitamin IV Therapy and Supplements: Maintaining Good Health Through Nature (RECRUITING)

Published literature

GreenMedInfo
D-Ribose Natural product Food compound Preclinical Moderate 10
No indexed hits
View evidence
Examine.com, GreenMedInfo
Zinc Natural product Nutraceutical Phase I Emerging 10
4 trials
View evidence

Registry trials

  • NCT04301609 — Clinical Trial to Assess the Improvement of Fatigue, Sleep Problems, Anxiety / Depression, Neurovegetatives Alterations and Quality of Life After the Administration of ImmunoVita® in Chronic Fatigue Syndrome Patients (COMPLETED) NA
  • NCT05605886 — Botulinum Toxin A in Patients With Myofascial Pain Syndrome With and Without Zinc Supplementation (UNKNOWN) EARLY_PHASE1
  • NCT07519824 — The Role of Bioelements in Fibromyalgia: Disease Activity or Depression-Anxiety? (COMPLETED)
  • NCT01469936 — Effect of PERMEAPROTECT on the Quality of Life of Patients With Fibromyalgia (UNKNOWN) NA

GreenMedInfo
Folate Natural product Nutraceutical Preclinical Emerging 10
5 trials
View evidence

Registry trials

  • NCT07013305 — Pre- and Post-Treatment Investigation of B12 and Folic Acid (Folate) Levels in Patients Receiving Antiepileptic (Anticonvulsant) Treatment for Fibromyalgia: Retrospective Study (COMPLETED)
  • NCT05067998 — The Benefits of Natural Medicine, Vitamin IV Therapy and Supplements: Maintaining Good Health Through Nature (RECRUITING)
  • NCT06969716 — Frequency of Fibromyalgia Syndrome in Elderly Patients Aged 80 and Above and Its Relationship With Geriatric Parameters (COMPLETED)
  • NCT01469936 — Effect of PERMEAPROTECT on the Quality of Life of Patients With Fibromyalgia (UNKNOWN) NA
  • NCT05357157 — Electroacupuncture Pain Treatment, Mechanical Hyperalgesia, Quality of Life & Expression of Mu+ B Cells in Fibromyalgia (RECRUITING)

GreenMedInfo
Dhea Natural product Food compound Preclinical Moderate 10 Examine.com
Olive Oil Natural product Nutraceutical Preclinical Emerging 10 GreenMedInfo
L-Carnitine Natural product Amino acid Preclinical Emerging 7
1 Cochrane 3 Trial pubs
View evidence
Examine.com
Saffron Natural product Botanical Preclinical Emerging 7
1 Cochrane
View evidence
Examine.com
Melatonin Natural product Nutraceutical Preclinical Emerging 7 GreenMedInfo
Probiotics Natural product Probiotic Preclinical Emerging 7 GreenMedInfo
Tryptophan Natural product Amino acid Preclinical Emerging 7 GreenMedInfo
Turmeric Natural product Botanical Preclinical Emerging 7 GreenMedInfo
SAMe (S-Adenosylmethionine) Natural product Nutraceutical Phase I Emerging 3 GreenMedInfo
Cannabidiol Natural product Food compound Preclinical Emerging 2 GreenMedInfo
D-Ribose Natural product Food compound Preclinical Emerging 0
No indexed hits
View evidence
Examine.com
Dhea Natural product Food compound Preclinical Emerging 0 Examine.com
Cannabis Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Palmitoylethanolamide Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Homeopathic Medicine: All Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
5-HTP (5-Hydroxytryptophan) Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Chlorella (Algae) Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Hydroxytyrosol Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Broccoli Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Malic Acid Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Chocolate Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Fruit: All Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Polyphenols Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Vegetables: All Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Sea Salt: Dead Sea Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Cellfood Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Oxygen Therapies Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Pycnogenol (Pine Bark) Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Delta-Tetrahydrocannabinol (THC) Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Homeopathic Medicine: Rhus Toxicodendron Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Magnesium: Transdermal Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Astaxanthin Natural product Food compound Preclinical Emerging 0 GreenMedInfo
Fisetin Natural product Food compound Preclinical Emerging 0 GreenMedInfo
Diosmetin Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Honokiol Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Lignans Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Psychedelics:All Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Bifidobacterium Infantis Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Capsaicin Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Mineral Water Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo

Alterations and therapeutics are aggregated from public databases (Open Targets, HPO, ChEMBL, DGIdb, and others). Natural agents are candidates from OSMF narrative reviews on opensourcemed.info/chronic-disease.html — not approved treatments. This page is for research orientation only — not medical advice.

Part of the Open Source Medicine Foundation Network

Open Source Medicine Foundation The OSMF hub — advancing open-source biomedical research infrastructure, tools, and evidence synthesis.
SpikeProtein.site Database and research resource on SARS-CoV-2 spike protein biology, persistence, and clinical implications.
Vaccine Data Navigator Open-access navigation tool for vaccine adverse event reporting and surveillance data.
VitalScan4PACVS Remote physiological monitoring study for post-acute COVID-19 vaccination syndrome.
PACVS Research Summit Annual summit convening researchers, clinicians, and patients on PACVS science.